Form 8-K - Current report:
SEC Accession No. 0001193125-25-143825
Filing Date
2025-06-23
Accepted
2025-06-20 19:29:11
Documents
13
Period of Report
2025-06-20
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d924424d8k.htm   iXBRL 8-K 28480
2 EX-99.1 d924424dex991.htm EX-99.1 6952
  Complete submission text file 0001193125-25-143825.txt   157832

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA inzy-20250620.xsd EX-101.SCH 2850
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE inzy-20250620_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inzy-20250620_pre.xml EX-101.PRE 11707
15 EXTRACTED XBRL INSTANCE DOCUMENT d924424d8k_htm.xml XML 3761
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

EIN.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39397 | Film No.: 251062686
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)